TFF Pharmaceuticals Completes Enrollment in Phase 1 Study Evaluating Inhaled Formulation of Niclosamide to Treat COVID-19

~ Complete Safety Data Anticipated by End of 1Q 2022 ~ Safety Management Committee Has Recommended 12 mg as Phase 2 Dose ~ Niclosamide is a Potent Inhibitor of SARS-CoV-2 with Activity Against Multiple Variants

Thank you for visiting Tailwinds Research. We are pleased to offer free research on select small and micro cap companies. It is free to join and we hope you’ll take the time to do so.

To create an account please click on this link.

If you already have an account, please log in here.


Please enter your comment!
Please enter your name here